# A Study of TAS-303 in Female Patients With Stress Urinary Incontinence

> **NCT02562807** · PHASE1 · COMPLETED · sponsor: **Taiho Pharmaceutical Co., Ltd.** · enrollment: 16 (actual)

## Conditions studied

- Stress Urinary Incontinence

## Interventions

- **DRUG:** TAS-303 18mg single-dose
- **DRUG:** Placebo 18mg single-dose
- **DRUG:** TAS-303 9mg single-dose
- **DRUG:** Placebo 9mg single-dose

## Key facts

- **NCT ID:** NCT02562807
- **Lead sponsor:** Taiho Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-10
- **Primary completion:** 2015-12
- **Final completion:** 2016-03
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2016-08-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02562807

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02562807, "A Study of TAS-303 in Female Patients With Stress Urinary Incontinence". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02562807. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*